APA (7th ed.) Citation

BS, W., E, S., MR, S., MR, G., MKB, P., M, A., . . . MJ, S. (2018). Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. European urology oncology, 1(6), 449. https://doi.org/10.1016/j.euo.2018.06.004

Chicago Style (17th ed.) Citation

BS, Woods, et al. "Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness." European Urology Oncology 1, no. 6 (2018): 449. https://doi.org/10.1016/j.euo.2018.06.004.

MLA (9th ed.) Citation

BS, Woods, et al. "Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness." European Urology Oncology, vol. 1, no. 6, 2018, p. 449, https://doi.org/10.1016/j.euo.2018.06.004.